Yorvipath denied as experimental or investigational by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Yorvipath as Experimental — and Why That Classification Is Contestable

Humana may classify a treatment as "experimental or investigational" when it determines the evidence does not yet meet its internal standard for proven clinical benefit. For Yorvipath (palopegteriparatide), an FDA-approved therapy for hypoparathyroidism, an experimental denial is particularly significant because FDA approval itself — following the agency's rigorous review of safety and efficacy data — is a strong counter-argument. Experimental denials on FDA-approved drugs succeed on appeal at a meaningful rate when the prescribing physician documents the established evidence base and guideline support.

## Why This Is Appealable

FDA approval is not equivalent to "experimental." The FDA grants approval only after reviewing clinical trial data for safety and efficacy in the specific population and indication. An insurer's internal evidence criteria that results in classifying an FDA-approved drug as experimental is subject to challenge under both ERISA and ACA external review standards. Reviewers — including independent IROs — are instructed to weigh the FDA-approval status of the therapy. Additionally, relevant endocrinology guideline organizations address hypoparathyroidism management; your prescriber can reference the applicable guideline body's position without needing to cite specific numbers.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): Submit a formal written internal appeal. Include a physician letter and published evidence. The insurer must provide a full-and-fair review with a qualified clinical reviewer.
• External review (ACA §2719): Experimental/investigational denials are explicitly eligible for external review under federal and most state laws. The IRO applies an evidence-based standard — FDA approval and guideline support weigh heavily. Window is typically up to four months; expedited option available.
• State insurance law: Some states impose additional protections against experimental denials for FDA-approved drugs. Check whether the plan is subject to state law or governed solely by ERISA.

## Documentation to Gather

1. FDA approval documentation — confirm the approval for the exact indication matching the patient's diagnosis. 2. Diagnosis records — laboratory confirmation of hypoparathyroidism, documented etiology, severity, and duration. 3. Treatment history — prior therapies attempted, duration, and documented outcomes, showing the clinical need. 4. Prescriber letter — the treating endocrinologist should address the FDA-approval basis, reference the relevant guideline organization's recognition of the therapy, and directly rebut Humana's experimental classification with a summary of the evidence. 5. Peer-reviewed literature summary — a brief, non-numerical narrative summary of the published evidence (the prescriber can characterize the evidence quality without citing specific statistics you cannot verify).

## Criteria-Mapping Strategy

Obtain Humana's published experimental/investigational policy and its Yorvipath-specific coverage determination. Identify the exact evidence criteria Humana applied. For each criterion, provide the corresponding evidence: FDA approval status, guideline organization recognition, and the prescriber's clinical assessment. If Humana's policy requires a specific level of evidence, confirm through the prescriber whether peer-reviewed studies exist that meet that level — and cite those studies by name and journal without quoting specific statistics.